Leyshon Griffiths

Leyshon GriffithsAssociate Professor in Medical Education and Honorary Consultant Urological Surgeon
Leyson Griffiths Headshot

Department: Molecular and Cell Biology, Leicester Medical School

Emailtrlg1@leicester.ac.uk

Address: University of Leicester, George Davies Centre, University Road, Leicester, LE1 7R

Website Links: https://www.researchgate.net/profile/Tr_Griffiths

Biography

I qualified from St. Bartholomew’s Hospital Medical School in London in 1989. After early posts at Cambridge (Downing College), London and Norwich, I obtained a research MD in Newcastle and won the national Patey Prize from the Surgical Research Society in 1996 for my work on ‘Role of P53 in Bladder Cancer’. I completed Urological surgical training in Newcastle and was appointed to my current post in Leicester in 2002. At Leicester Medical School, I have a teaching-focused post where I am Head of Year 4 and Undergraduate Professionalism Curriculum Lead. I am a member of the UK Council for Teachers of Professionalism.

I have a special surgical and clinical interest in non-muscle invasive bladder cancer, in particular intravesical treatments, hyperthermia and enhanced cystoscopy. I also have research interests in pedagogy and patient safety.

Qualifications

  • BSc MBBS MD FRCS Ed (Urol) SFHE

Teaching

My focus is on Medical Education and in particular teaching medical students on Urology, Urological cancer, Professionalism and Diversity

Publications

  1. Fernando A, Fowler S, Van Hemelrijck M, O'Brien T; British Association of Urological Surgeons (BAUS). (2017) Who is at risk of death from nephrectomy? An analysis of thirty-day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit. BJU Int; 120(3):358-364.
  2. Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, et al; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z. (2016) Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS- genotyping array. Br J Cancer; 114(8):945-52.
  3. Fernando A, Fowler S, O'Brien T; British Association of Urological Surgeons (BAUS). (2016) Nephron-sparing surgery across a nation - outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy audit. BJU Int; 117(6):874-82.
  4. Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, et al. (2015) Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet; 24(19):5589-602.
  5. Jackson BL, Mohammed A, Mayer N, Dormer J, Griffiths TR. (2016) Is immediate radical cystectomy necessary for all patients with non-muscle invasive micropapillary bladder cancer? Urol Int; 96(1):32-8.
  6. Kockelbergh R, Griffiths L. (2016) Renal Tumour Biopsy – A new standard of care? Eur Urol; 69(4):674-5. (Editorial)
  7. Zelhof B, McIntyre IG, Fowler SM, Napier-Hemy RD, Burke DM, Grey BR; British Association of Urological Surgeons. Nephrectomy for benign disease in the UK: results from the British Association of Urological Surgeons nephrectomy database. (2016) BJU Int; 117(1):138-44.
  8. Henderson JM, Fowler S, Joyce A, Dickinson A, Keeley FX; BAUS. (2015) Perioperative outcomes of 6042 nephrectomies in 2012: surgeon-reported results in the UK from the British Association of Urological Surgeons (BAUS) nephrectomy database. BJU Int; 115(1):121-6.
  9. Griffiths TR, Kockelbergh RC. (2014) A green light for blue light…without single-dose chemotherapy. Eur Urol; 66(5):872-3. (Editorial)
  10. Bowman KJ, Al-Moneef MM, Sherwood BT, Colquhoun AJ, Goddard JC, Griffiths TR, Payne D, Singh S, Butterworth PC, Khan MA, Summerton DJ, Steward WP, McKelvey-Martin VJ, McKeown SR, Kockelbergh RC, Mellon JK, Symonds RP, Jones GD. (2014) Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo. Int J Cancer; 134(5):1102-11.
  11. Griffiths TR; on behalf of Action on Bladder Cancer (Charity Registration Number: 1138532). (2013) Current perspectives in bladder cancer management. Int J Clin Pract; 67(5):435-448.
  12. Bekema HJ, MacLennan S, Imamura S, Lam TB, Stewart F, Scott N, MacLennan G McClinton S, Griffiths TR, Skolarikos A, MacLennan SJ, Sylvester R, Ljungberg B, N’Dow J. (2013) Eur Urol; 64(5):799-810.
  13. Sun Y, Cheng MK, Griffiths TR, Mellon JK, Kai B, Kriajevska M, Manson MM. (2013) Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation. Curr Cancer Drug Targets; 13(1):57-68.
  14. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal, AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Dahm P, Canfield SE, McClinton S, Griffiths TR, Ljungbery B, N’Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. (2012) Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol; 62(6):1097-117.
  15. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J. (2012) Systematic review of oncological outcomes following surgical management of localised renal cancer. UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Eur Urol; 61(5):972-93. Erratum in: Eur Urol. 2012 Jul;62(1):193.
  16. Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, Cook JA, Fraser C, Griffiths TR; Aberdeen Technology Assessment Review (TAR) Group. (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care; 27(1):3-10.
  17. Stephenson JA, Green CA, Bukhari SS, Griffiths TR. (2011) Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk?. BJU Int; 108(4): E155.
  18. Maclennan SJ, Maclennan SJ, Imamura M, Omar MI, Vale L, Lam T, Royle P, Royle J, Swami S, Pickard R, McClinton S, Griffiths TR, Dahm P, N'dow J; UCAN Care Pathway Development Group. (2011) Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World J Urol; 29(3):291-301.
  19. Mowatt G, Zhu S, Kilinzo M, Biachie C, Fraser C, Griffiths TR, N’Dow J, Nabi G, Cook J, Vale L. (2010) Systematic review of the clinical and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess; 14(4):1-331.
  20. Goebell PJ, Groshen SG, Schmitz-Dräger BJ; International Study-Initiative on Bladder Cancer (ISBC). (2010) P53 immunohistochemistry in bladder cancer- a new approach to an old question. Urol Oncol; 28(4):377-88.
  21. Gkougkousis EG, Mellon JK, Griffiths TR. (2010) Management of the distal ureter during nephroureterectomy for upper urinary tract transitional cell carcinoma: A review. Urol Int; 85(3): 249-56.
  22. Ayres BE, Griffiths TRL, Persad RA. (2010) Is the role of intravesical bacillus Calmette-Guerin in non-muscle invasive bladder cancer changing? BJU Int; 105 Suppl 2: 8-13.
  23. Bunce C, Ayres BE, Griffiths L, Mostafid H, Kelly J, Persad R, Kockelbergh R. (2010) The role of Hexvix (hexylaminolevulinate) in the diagnosis and follow-up of non-muscle invasive bladder cancer. BJU Int; 105 Suppl 2:2-7.
  24. Eeles RA, et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet; 41(10):1116-21.
  25. Al Olama AA, et al. (2009) Links multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet; 41(10):1058-60.
  26. Sayan AE, Griffiths TR, Pal R, Ruddick A, Yagci T, Edwards R, Mayer N, Qazi H, Goyal S, Fernandez S, Straatman K, Jones G, Bowman K, Colquhoun A, Mellon JK, Kriajevska M, Tulchinsky E. (2009) SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA; 106 (35):14884-9.
  27. McHugh LA, Sayan AE, Meljvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK, Krajevska M. (2009) Lapatinib, a dual inhibitor of ErbB-1/2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol; 34(4):1155-63.
  28. Griffiths TR. (2009) Editorial comment on: Thirty-day mortality after nephrectomy: Clinical implications for informed consent. Eur Urol; 56(6): 891-1104.
  29. Walton TJ, Heads S, Parkinson RJ, Griffiths TR. (2008) An improvised delivery system for irrigation. Ann R Coll Surg Engl; 90:429-30.
  30. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. (2007) Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens – evidence of schedule-dependent synergy. Urology; 69:390-4.
  31. Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, Kriajevska M. (2007) Metastasis-asociated protein S100A4: spotlight on its role in cell migration. Current Cancer Drug Targets; 7:217-28.
  32. Bodiwala D, Jeyarajah S, Terry TR, Griffiths TR. (2007) The first semen analysis after vasectomy: timing and definition of success. BJU Int; 99:727-8.
  33. Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TRL, Gescher AJ. (2005) Role of oxidative stress in the pathogenesis of prostate cancer and the potential for chemoprevention. Eur J Cancer; 41:61-70.
  34. Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP, Mellon JK. (2006) Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer. Clin Oncol; 18:702-9.
  35. Heer R, Dorkin TJ, Byrne RL, Griffiths TR, Rangecroft L. (2004) A prospective audit of hypospadias in a regional paediatric centre. Eur J Pediatr Surg; 14:328-32.
  36. McHugh LA, Griffiths TRL. (2004) Letter re: T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int; 94: 93.
  37. Griffiths TRL, Mellon JK. (2004) Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med Journal; 80:320-7.
  38. McHugh LA, Griffiths TRL, Kriajevska M, Symonds RP, Mellon JK. (2004) Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology; 63:619-24.
  39. Skolarikos A, Griffiths TRL, Thomas DJ, Neal DE, Kelly JD. (2003) Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology; 61:1146-50.
  40. Griffiths TRL, Charlton M, Neal DE, Powell PH. (2002) Treatment of carcinoma in situ with intravesical bacillus calmette-guerin without maintenance. J Urol; 167:2408-12.
  41. Qureshi KN, Griffiths TRL, Robinson MC, Marsh C, Roberts JT, Lunec J, Neal DE, Mellon JK. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. (2001) Int J Radiat Oncol Biol Phys,; 51:1234-40.
  42. Cresswell J, Robertson H, Neal DE, Griffiths TRL, Kirby JA. (2001) Distribution of lymphocytes with the αEβ7 phenotype in normal human urothelium and bladder carcinomas. Clin Exp Immunol; 126: 397-402.
  43. Griffiths TRL, Mellon JK. Human papillomavirus and urological tumours: II. (2000) Role in bladder, prostate, renal and testis cancer. BJU Int; 85:211-17.
  44. Qureshi KN, Griffiths TRL, Robinson MC, Marsh C, Roberts JT, Hall RR, Lunec J, Neal DE. (1999) TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res; 5:3500-7.
  45. Pettit SJ, Ali S, O’Flaherty E, Griffiths TRL, Neal DE, Kirby JA. (1999) Bladder cancer immunogenicity: Expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro. Clin Exp Immunol; 116: 48-56.
  46. Griffiths TRL, Mellon JK. (1999) Human papillomavirus and urological tumours: I. Basic Science and role in penile cancer. BJU Int; 84:579-86.
  47. Abdel-Fattah R, Challen C, Griffiths TRL, Robinson MC, Neal DE, Lunec J. (1998) Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer; 77:2230-8.
  48. Griffiths TRL, Neal DE. (1997) Localised prostate cancer - Early intervention or expectant therapy? J Royal Soc Med; 90:665-9.
  49. Griffiths TRL, Brotherick I, White MD, Bishop RI, Horne CHW, Shenton BK, Neal DE, Mellon JK. (1996) Cell adhesion molecules in patients with bladder cancer: Soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer; 74:579-584
  50. Leung H, Griffiths TRL, Neal DE. (1996) Bladder cancer. Postgrad Med J; 72:719-24.
  51. Griffiths TRL, Mellon JK, Pyle GA, Shenton BK, Neal DE. (1995) P53 and ploidy assessed by flow cytometry in bladder washings in TCC. Br J Urol; 76:575-579.
  52. Cohen B, Griffiths L, Dandy DJ. (1992) Case Report. Arteriovenous fistula following arthroscopic synevectomy in a haemophiliac. Arthroscopy: J Arthroscopic and Related Surgery; 8 (3):373-374.
  53. Johnston SRD, Hammond A, Griffiths TRL, Greenwood R, Clarke CRA. (1989) Subarachnoid haemorrhage. Can we do better? J Royal Soc Med; 82 (12):721-724.

Chapters

  1. Jackson B, Griffiths TRL. Renal carcinoma and other tumours. In Barratt J, Topham P, Harris K eds. Oxford Desk Reference Nephrology. Oxford: Oxford University Press. Chapter (In Press 2018)
  2. Jackson B, Griffiths TRL, Mellon JK. Intravesical chemotherapy for bladder cancer. In Vinod H. Nargund, Derek Raghavan, Howard M. Sandler eds. Urological Oncology. Springer, 2015: Chapter 31
  3. Jackson B, Griffiths TRL, Mellon JK. Superficial bladder cancer. In Vinod H. Nargund, Derek Raghavan, Howard M. Sandler ed. Urological Oncology. Springer, 2015: Chapter 30
  4. Griffiths TRL, Mellon JK. Bladder cancer. In Nargund V ed., Handbook of Uro-oncology. London: Springer-Verlag, 2008: Chapter 18.
  5. Griffiths TRL, NJ Mayer. Transitional cell carcinoma of the bladder. In Mundy AR, Fitzpatrick JM, Neal DE, George JR eds, The Scientific Basis of Urology (3rd edition) London: Taylor & Francis Group, 2010: Chapter 24.
  6. Griffiths TRL, NJ Mayer. Renal carcinoma and other tumours. In Barratt J, Topham P, Harris K eds. Oxford Desk Reference Nephrology. Oxford: Oxford University Press, 2008: Chapter 17
  7. Griffiths TRL, Mellon JK. A scientific understanding of the development of penile tumours. In Waxman J ed, Urological Oncology: science and treatment. London: Springer-Verlag, 2005: Chapter 2
  8. Griffiths TRL, Mellon JK. Transitional cell carcinoma of the bladder. In Mundy AR, Fitzpatrick JM, Neal DE, George JR eds, The Scientific Basis of Urology (2nd edition). London: Taylor & Francis Group, 2004: Chapter 23
  9. Griffiths TRL, Neal DE. Bladder cancer: Natural history. In Hamdy FC, Basler J, Neal D, Catalona W eds, Management of Urologic malignancies. London: Churchill Livingstone, 2002: Chapter 2:
  10. Rajjayabun PH, Griffiths TRL, Mellon JK. Human papillomavirus in Urological Oncology. In Waxman J ed, Treatment Options in Urological Cancer. Oxford: Blackwell Science Ltd., 2002: Chapter 21.
  11. Griffiths TRL, Neal DE. Transitional cell carcinoma of the bladder. In Mundy AR, Fitzpatrick JM, Neal DE, George JR eds, The Scientific Basis of Urology. Oxford: Isis Medical Media Ltd., 1999: Chapter 18.
  12. Griffiths TRL, Neal DE. The management of superficial bladder cancer. In Johnston CD, Taylor I eds, Recent Advances in Surgery, No. 19. Edinburgh: Churchill Livingstone, 1996: Chapter 5.

Research

Current Projects

  • Development and validation of a marketable Healthcare Normal Operations Safety Audit patient safety education and in loco risk-management tool (University of Leicester)
  • Staff experiences in robotic theatres (University of Leicester)
  • CALIBER trial: Phase II randomised feasibility study of chemoresection and surgical management in low risk, non-muscle-invasive bladder cancer (National Institute for Health Research)

Current Clinical Research - Investigator:

I am currently the Principal Investigator for DETECT 2, Co-Investigator for Add Aspirin and PATCH trials.

Past Projects

HYMM trial: A randomised controlled trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin in patients with recurrence of non muscle-invasive bladder cancer following BCG induction (Cancer Research UK)

Supervision

  • MD – Staff experiences in robotic theatres

Share this page:

Contact Details

Department of Molecular and Cell Biology

T: +44(0)116 229 7038
E: MolCellBiol@le.ac.uk

Map with link to google maps geotag of Henry Wellcome

Henry Wellcome Building - University of Leicester, Lancaster Rd, LE1 7HB

Postal: Henry Wellcome Building, University of Leicester, Leicester, LE1 7RH

Directions on Arrival to The Henry Wellcome Building

Student complaints procedure

Accessibility

AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Henry Wellcome Building.